Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Average Rating of "Buy" by Analysts

Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Get Free Report) have been assigned an average rating of "Buy" from the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation, five have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $66.67.

A number of research analysts have recently issued reports on the company. HC Wainwright raised Tarsus Pharmaceuticals to a "buy" rating and set a $72.00 price objective on the stock in a research note on Tuesday, May 27th. Jefferies Financial Group increased their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the company a "buy" rating in a report on Thursday, March 6th. The Goldman Sachs Group raised their price target on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the stock a "neutral" rating in a research report on Monday, May 5th. Wall Street Zen downgraded Tarsus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Barclays dropped their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, February 26th.

Insider Buying and Selling at Tarsus Pharmaceuticals

In related news, CEO Bobak R. Azamian sold 6,000 shares of Tarsus Pharmaceuticals stock in a transaction on Monday, March 24th. The shares were sold at an average price of $50.00, for a total value of $300,000.00. Following the sale, the chief executive officer now owns 824,106 shares in the company, valued at $41,205,300. The trade was a 0.72% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 8.97% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Tarsus Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of TARS. Rhumbline Advisers raised its stake in Tarsus Pharmaceuticals by 2.1% in the fourth quarter. Rhumbline Advisers now owns 49,534 shares of the company's stock worth $2,743,000 after buying an additional 1,019 shares in the last quarter. Nations Financial Group Inc. IA ADV purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $332,000. Y Intercept Hong Kong Ltd purchased a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $837,000. Bank of New York Mellon Corp raised its position in shares of Tarsus Pharmaceuticals by 0.5% in the 4th quarter. Bank of New York Mellon Corp now owns 101,928 shares of the company's stock worth $5,644,000 after acquiring an additional 498 shares in the last quarter. Finally, Oppenheimer & Co. Inc. purchased a new position in shares of Tarsus Pharmaceuticals in the 4th quarter valued at approximately $227,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Tarsus Pharmaceuticals Price Performance

Shares of TARS stock traded down $0.42 during trading hours on Tuesday, hitting $40.66. 572,366 shares of the company's stock were exchanged, compared to its average volume of 698,659. The company has a market capitalization of $1.71 billion, a PE ratio of -14.87 and a beta of 0.83. The company has a current ratio of 5.57, a quick ratio of 5.54 and a debt-to-equity ratio of 0.21. Tarsus Pharmaceuticals has a 12-month low of $20.08 and a 12-month high of $57.28. The business's 50 day simple moving average is $45.21 and its 200-day simple moving average is $48.34.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The company had revenue of $78.34 million for the quarter, compared to analyst estimates of $72.50 million. Tarsus Pharmaceuticals had a negative net margin of 44.91% and a negative return on equity of 39.72%. On average, equities research analysts anticipate that Tarsus Pharmaceuticals will post -3.17 earnings per share for the current year.

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.